Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 5/20 | 0.41 |
| ▸ | HRH1 | P35367 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834873 | 0.98 | TAS1R3 (0.43) | S1PR1S1PR5S1PR3PPARGPPARA | |
| SCHEMBL17834885 | 0.96 | S1PR1 (0.41) | S1PR1S1PR5S1PR3PPARGPPARA | |
| SCHEMBL17834743 | 0.96 | S1PR1 (0.42) | S1PR1S1PR5HRH3RARBHRH2 | |
| SCHEMBL17834883 | 0.96 | GAA (0.44) | S1PR1S1PR5HRH3RARBHRH2 | |
| SCHEMBL17834871 | 0.96 | S1PR1 (0.43) | S1PR1S1PR5S1PR3HRH3RARB | |
| SCHEMBL17834741 | 0.94 | S1PR1 (0.42) | S1PR1S1PR5HRH3RARBHRH2 | |
| SCHEMBL17834740 | 0.94 | S1PR1 (0.41) | S1PR1S1PR5HRH3RARBHRH2 | |
| SCHEMBL22384445 | 0.94 | S1PR5 (0.47) | S1PR1S1PR5S1PR3PPARGPPARA | |
| SCHEMBL17834892 | 0.94 | S1PR1 (0.42) | S1PR1S1PR5HRH3RARBHRH2 | |
| SCHEMBL17834752 | 0.94 | S1PR5 (0.47) | S1PR1S1PR5S1PR3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR5 889/4885S1PR3 529/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | S1PR1 486/4885S1PR5 889/4885S1PR3 529/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | S1PR1 523/4885S1PR5 939/4885S1PR3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.